Pharmaceutical Contract Manufacturing and Research Services Market Size & Growth Forecast 2027–2036, By Segments (Service), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Pharmaceutical Contract Manufacturing and Research Services Market size stood at USD 309.2 billion in 2026 and is predicted to grow at a 6.84% CAGR from 2027 to 2036, attaining USD 599.21 billion by 2036. The industry revenue for 2027 is calculated at USD 327.01 billion.
Get more details on this report
Request Free Sample ReportPharmaceutical Contract Manufacturing and Research Services Market Intelligence Snapshot
Regional Market Dynamics
- Asia Pacific holds a 44.52% share due to strong manufacturing capacity, cost-efficient operations, and a well-established outsourcing ecosystem supporting end-to-end pharmaceutical development and production services.
- Asia Pacific is expanding at an 8.14% CAGR, driven by scalable infrastructure, high utilization of manufacturing capacity, and increasing outsourcing of development and commercial production activities.
Segment Momentum
- Manufacturing held a 64.12% share in 2026 because pharmaceutical companies depend on external partners for scalable production capacity, specialized infrastructure, regulatory compliance, and reliable commercial supply.
- Research is the fastest-growing segment as drug developers increasingly outsource discovery and preclinical activities to gain technical expertise, development speed, and greater flexibility without expanding internal capabilities.
Market Expansion Drivers
- Cost-efficient outsourcing and CDMO expansion driving pharmaceutical manufacturing delegation.
- Rising biologics and biosimilars complexity increasing reliance on specialized manufacturing partners.
- Expansion of Asia Pacific manufacturing hubs strengthening global pharma supply chains.
Leading Market Participants
- Major players in the pharmaceutical contract manufacturing and research services market include Lonza Group AG (Switzerland), Catalent, Inc. (United States), Thermo Fisher Scientific Inc. (United States), Boehringer Ingelheim International GmbH (Germany), AbbVie Inc. (United States), Grifols, S.A. (Spain), Recipharm AB (Sweden), Siegfried Holding AG (Switzerland), Fujifilm Diosynth Biotechnologies (Japan), Samsung Biologics Co., Ltd. (South Korea).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 309.2 billion
- 2027 Estimated Market Size: USD 327.01 billion.
- Projected Market Size: USD 599.21 billion by 2036
- Growth Forecast: 6.84% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: Asia Pacific
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Manufacturing (Service)
- Emerging Opportunity Segment: Research (Service)
Market Growth Drivers and Industry Trends
Cost-efficient outsourcing and CDMO expansion driving pharmaceutical manufacturing delegation
Pharmaceutical companies are increasingly delegating manufacturing and selected development activities to specialized external providers to control operational costs, improve resource allocation, and gain access to established production capabilities. The pharmaceutical contract manufacturing and research services market is benefiting from this shift as companies seek flexible manufacturing capacity without committing equivalent levels of capital to internal facilities, equipment, and specialized personnel. Expansion among contract development and manufacturing organizations is further strengthening the outsourcing ecosystem by providing capabilities across development, process optimization, clinical supply production, commercial manufacturing, and related technical services.
Rising biologics and biosimilars complexity increasing reliance on specialized manufacturing partners
The growing complexity of biologic medicines and biosimilars requires sophisticated development, production, quality control, and process-management capabilities that can be difficult to establish internally. This trend will propel pharmaceutical contract manufacturing and research services market growth as pharmaceutical developers increasingly engage specialized partners with expertise in complex biological production processes, formulation, analytical development, and scale-up activities. External manufacturing relationships can also help companies access specialized infrastructure and technical knowledge as product pipelines expand into therapies requiring more demanding production environments and stringent quality controls.
Expansion of Asia Pacific manufacturing hubs strengthening global pharma supply chains
The development of pharmaceutical manufacturing capabilities across asia pacific is increasing the region's importance within international drug production and outsourcing networks. For the pharmaceutical contract manufacturing and research services market, expanding manufacturing hubs provide pharmaceutical companies with broader access to production capacity, technical expertise, and integrated supply-chain capabilities across key stages of drug development and manufacturing. The strengthening of regional infrastructure also supports greater diversification of pharmaceutical production footprints, enabling companies to establish partnerships with specialized providers while connecting manufacturing operations with broader global supply chains.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Cost-efficient outsourcing and CDMO expansion driving pharmaceutical manufacturing delegation | 2.50% | High | Asia Pacific, North America | High | Near Term |
| Rising biologics and biosimilars complexity increasing reliance on specialized manufacturing partners | 2.30% | High | Global | High | Mid Term |
| Expansion of Asia Pacific manufacturing hubs strengthening global pharma supply chains | 2.00% | Moderate | Asia Pacific | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
Asia Pacific (Largest & Fastest-Growing Region)
Asia Pacific led the pharmaceutical contract manufacturing and research services market, capturing a 44.52% share in 2026, while also representing the fastest-growing regional market. Its strong position reflects the region’s expanding pharmaceutical manufacturing base, growing research capabilities, and increasing adoption of outsourced development and production activities. Pharmaceutical companies are increasingly using contract partners to access specialized expertise, optimize manufacturing resources, and support complex drug development requirements. Favorable manufacturing ecosystems, expanding technical talent pools, improving research infrastructure, and increasing investment in pharmaceutical production are reinforcing the region’s attractiveness for contract services. At the same time, growing healthcare demand and the expansion of pharmaceutical markets across emerging economies are creating a broader pipeline of opportunities for research, development, and manufacturing outsourcing.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
High-quality pharma productionIn Germany, pharmaceutical contract manufacturing and research services market activity is shaped by high-quality GMP manufacturing standards. Germany prioritizes reliable contract manufacturing and research services supporting regulated pharmaceutical development and export-oriented drug production.
France 🇫🇷
Clinical-pharma integrationIn France, pharmaceutical contract manufacturing and research services market activity is influenced by close integration between clinical research and manufacturing networks. France emphasizes high-compliance outsourcing services supporting drug development and regulatory approval pathways.
Italy 🇮🇹
Outsourcing-driven pharma growthIn Italy, pharmaceutical contract manufacturing and research services market demand is shaped by increasing reliance on outsourcing for drug development and production. Italy focuses on leveraging external expertise to support pharmaceutical innovation and regulatory compliance.
Japan 🇯🇵
Process-controlled outsourcingIn Japan, pharmaceutical contract manufacturing and research services market demand reflects strong process control and quality assurance expectations. Japan emphasizes carefully managed outsourcing partnerships supporting pharmaceutical innovation and consistent production quality.
South Korea 🇰🇷
CDMO ecosystem expansionIn South Korea, pharmaceutical contract manufacturing and research services market growth is supported by rapid expansion of CDMO capabilities. South Korea focuses on integrating global pharmaceutical supply chains through scalable manufacturing and research outsourcing services.
United States 🇺🇸
Biopharma outsourcing scaleIn the U.S., pharmaceutical contract manufacturing and research services market demand is driven by large-scale biopharma outsourcing and pipeline acceleration. The U.S. emphasizes integrated CRO-CDMO capabilities supporting drug discovery, clinical trials, and commercial manufacturing for innovative therapeutics.
Segment Leadership and Growth Trends
Pharmaceutical Contract Manufacturing and Research Services Market Share (%), by Service, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportService Segment Analysis: Manufacturing (Largest Segment) vs Research (Fastest-Growing Segment)
Manufacturing held the largest share of the pharmaceutical contract manufacturing and research services market in 2026, representing 64.12% of the market, supported by pharmaceutical companies' continued reliance on external production capabilities to improve manufacturing flexibility and operational efficiency. Contract manufacturing allows drug developers to access specialized facilities, production technologies, quality systems, and technical expertise while reducing the need to expand internal manufacturing infrastructure. Increasing complexity in pharmaceutical production and the need to manage production capacity efficiently are reinforcing demand for outsourced manufacturing services.
Research services are projected to grow at the fastest pace as pharmaceutical developers increasingly seek external expertise across drug discovery, development, analytical testing, and related research activities. Outsourcing research can provide access to specialized scientific capabilities and technologies while helping development teams manage complex workflows more efficiently. Growing emphasis on accelerating drug development and controlling research costs is encouraging broader use of external research partners across the pharmaceutical development process.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Service | Manufacturing, Research | Manufacturing | Research |
Competitive Landscape and Market Positioning
Prominent players in the pharmaceutical contract manufacturing and research services market:
1. Lonza Group AG (Switzerland)
2. Catalent Inc. (United States)
3. Thermo Fisher Scientific Inc. (United States)
4. Boehringer Ingelheim International GmbH (Germany)
5. AbbVie Inc. (United States)
6. Grifols S.A. (Spain)
7. Recipharm AB (Sweden)
8. Siegfried Holding AG (Switzerland)
9. Fujifilm Diosynth Biotechnologies (Japan)
10. Samsung Biologics Co. Ltd. (South Korea)
The pharmaceutical contract manufacturing and research services market is witnessing heightened consolidation and capacity expansion initiatives aimed at supporting growing outsourcing demand. Organizations are enhancing integrated service capabilities spanning drug development, clinical manufacturing, and commercial-scale production. Increased focus on flexible manufacturing technologies and global delivery networks is strengthening competitiveness within the market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Lonza Group AG (Switzerland) | |||||||
| Catalent Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Boehringer Ingelheim International GmbH (Germany) | |||||||
| AbbVie Inc. (United States) | |||||||
| Grifols S.A. (Spain) | |||||||
| Recipharm AB (Sweden) | |||||||
| Siegfried Holding AG (Switzerland) | |||||||
| Fujifilm Diosynth Biotechnologies (Japan) | |||||||
| Samsung Biologics Co. Ltd. (South Korea). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Lonza | Jan-25 | Lonza announced the planned divestment of its Capsules & Health Ingredients business. This strategic restructuring is intended to sharpen the company's focus on its core CDMO operations, allowing for prioritized investment and resource allocation toward high-growth biopharmaceutical manufacturing and development services. |
| WuXi STA | 2025 | WuXi STA introduced integrated continuous manufacturing technologies for pharmaceutical production. By implementing these advanced manufacturing processes, the company aims to improve production efficiency, shorten development cycles, and offer clients more scalable and cost-effective solutions for the manufacture of complex small-molecule drugs. |
| Thermo Fisher Scientific | Oct-24 | Thermo Fisher Scientific launched "Accelerator Drug Development," an integrated end-to-end service suite spanning small and large molecule drug substance manufacturing, clinical supply, research, and commercialization. This platform is designed to consolidate the drug development value chain, significantly accelerating timelines from discovery through to market entry. |
| Lonza | Mar-24 | Lonza acquired a large-scale biologics manufacturing facility in Vacaville, California, from Roche/Genentech. This acquisition adds significant production capacity to Lonza's network, allowing the company to accommodate the increasing demand for commercial-scale biologics manufacturing and supporting its long-term growth strategy in the biopharmaceutical outsourcing market. |
| Samsung Biologics | 2024 | Samsung Biologics successfully expanded its large-scale biologics manufacturing facilities to meet global demand for outsourced production. The capacity increase enhances the company's ability to support major biopharmaceutical partners in commercial-scale production, reinforcing its competitive positioning as a leading global CDMO for complex biologics. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Pharmaceutical Contract Manufacturing and Research Services Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Molecule Modality | Small-Molecule Drugs, Biologics, Vaccines, Advanced Therapies |
| Client Type | Large Pharmaceutical Companies, Biotechnology Companies, Generic Drug Manufacturers, Specialty Pharmaceutical Companies |
| Contract Model | Project-Based Contracts, Long-Term Supply Agreements, Full-Service Development and Manufacturing Agreements, Dedicated Capacity Agreements |
Pharmaceutical Contract Manufacturing and Research Services Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Integrated CRDMO Partner Benchmarking |
|
| Global Manufacturing and Research Hub Attractiveness |
|
| Pharma Pipeline-Driven Capacity Demand Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much is the pharmaceutical contract manufacturing and research services market worth?
How is the pharmaceutical contract manufacturing and research services industry expected to grow over the next 10 years?
How is the shift toward integrated CDMO models transforming pharmaceutical manufacturing strategies?
What factors are driving geographic and technical realignment in pharmaceutical contract manufacturing networks?
Why is Manufacturing the largest service segment in the pharmaceutical contract manufacturing and research services market?
What is supporting the rapid growth of the Research segment in the pharmaceutical contract manufacturing and research services market?
Why does Asia Pacific lead the pharmaceutical contract manufacturing and research services market?
What is supporting continued growth in Asia Pacific’s contract manufacturing and research services market?
What are the key competitors in the pharmaceutical contract manufacturing and research services landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization